No products in the cart.
Rubraca (rucaparib) online
Roll over image to zoom in
Click to open expanded view
What is Rubraca (rucaparib) for?
Rubraca (rucaparib) is indicated as monotherapy for:
the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer, who have been treated with two or more chemotherapies1. Patients should be selected for therapy based on the FDA-approved FoundationFocus CDxBRCA test (Foundation Medicine Inc.)2,1. Approximately 15 to 20% of patients with ovarian cancer have a BRCA gene mutation3.
for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy1.
How does Rubraca (rucaparib) work?
BRCA genes are involved with repairing damaged DNA and normally work to prevent tumour development. However, mutations of these genes may lead to certain cancers, including ovarian cancers. Rubraca (rucaparib) is a poly ADP-ribose polymerase (PARP) inhibitor that blocks an enzyme involved in repairing damaged DNA. By blocking this enzyme, DNA inside the cancerous cells with damaged BRCA genes may be less likely to be repaired, leading to cell death and possibly a slowdown or stoppage of tumour growth3.
Where has Rubraca (rucaparib) been approved?
Rubraca (rucaparib) was approved by:
Food and Drug Administration (FDA), USA:
on December 19, 2016, for the treatment of patients with deleterious BRCA mutation (germline and/or somatic) associated advanced ovarian cancer who have been treated with two or more chemotherapies1
on April 6, 2018, for the for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy1.
How is Rubraca (rucaparib) taken?
The standard dosage is:
600 mg orally twice daily.
Patients should be monitored for hematologic toxicity at baseline and monthly thereafter, and use of Rubraca (rucaparib) should be discontinued if myelodysplastic syndrome (MDS) / acute myeloid leukemia (AML) is confirmed1.
Complete information about Rubraca (rucaparib) dosage and administration can be found in the resources section.
Note: Consult your treating doctor for personalised dosing.
Are there any known side effects or adverse reactions of Rubraca (rucaparib)?
Common adverse reactions
The most common adverse reactions listed in the prescribing information include:
dysgeusia (distortion of the sense of taste)
thrombocytopenia (deficiency of platelets in the blood)
dyspnea (difficult breathing)1.
Serious adverse reactions
The serious adverse reactions listed in the prescribing information include:
myelodysplastic syndrome/acute myeloid leukemia (MDS/AML).
Use in specific populations
Rubraca (rucaparib) can be fatal for a fetus, it is advised to avoid pregnancies and breast feeding.
For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1.